ORIC Pharmaceuticals, Inc. (ORIC)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

240 E. GRAND AVE. SOUTH SAN FRANCISCO, CA 94080

ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC's other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.

Data as of 2021-09-19 13:27:00 -0400
Market Cap991.592 Million Shares Outstanding39.318 Million Avg 30-day Volume231.12 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.3 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.61349 52-week High/Low40.81 / 15.67 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) -30.9007
Data provided by IEX Cloud
View SEC Filings from ORIC instead.

View recent insider trading info

Funds Holding ORIC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ORIC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

23.6 Thousand total shares from 11 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HEYMAN RICHARD A.

  • Director
228,772 2021-09-14 9

CHACKO JACOB PRESIDENT AND CEO

  • Officer
  • Director
2,652 2021-09-14 10

HOERTER STEVEN L.

  • Director
0 2021-08-13 2

GORDON CARL L

  • Director
  • 10% Owner
16,625 2021-06-16 6

KUNKEL LORI ANNE

  • Director
16,625 2021-06-16 1

DIER MARDI

  • Director
16,625 2021-06-16 1

SVENNILSON PETER

  • Director
  • 10% Owner
16,625 2021-06-16 1

SCHELLER RICHARD H

  • Director
39,092 2021-05-20 5

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • Director
2,212,571 2021-03-29 5

MULTANI PRATIK S CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-01 1

PISCITELLI DOMINIC CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-01 1

TOPSPIN FUND L.P.

TOPSPIN BIOTECH FUND II, L.P.

LG MANAGEMENT, LLC

GUTHART LEO

  • 10% Owner
No longer subject to file 2020-11-04 1

COLUMN GROUP II, LP

COLUMN GROUP II GP, LP

GOEDDEL DAVID V

  • 10% Owner
  • GENERAL PARTNERMANAGING PARTNER
4,768,181 2020-04-28 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CHACKO JACOB - Director - Officer PRESIDENT AND CEO

2021-09-16 18:17:32 -0400 2021-09-15 S 3,736 $25.06 d 2,652 direct yes -2.6963 -5.8684 0.0 1 -5.8684 6

HEYMAN RICHARD A. - Director see footnote

2021-09-16 18:19:21 -0400 2021-09-15 S 682 $25.03 d 216,272 indirect yes -2.6963 -5.8684 0.0 1 -5.8684 6

HEYMAN RICHARD A. - Director see footnote

2021-09-16 18:19:21 -0400 2021-09-14 S 706 $25.05 d 216,954 indirect yes -2.6963 -5.8684 0.0 1 -5.8684 6

CHACKO JACOB - Director - Officer PRESIDENT AND CEO

2021-09-16 18:17:32 -0400 2021-09-14 S 4,420 $25.05 d 6,388 direct yes -2.6963 -5.8684 0.0 1 -5.8684 6

CHACKO JACOB - Director - Officer PRESIDENT AND CEO

2021-09-14 16:01:22 -0400 2021-09-13 S 2,801 $25.02 d 10,808 direct yes -1.9553 -4.1101 0.6385 3 -4.2698 5

HEYMAN RICHARD A. - Director see footnote

2021-09-14 16:03:31 -0400 2021-09-13 S 601 $25.01 d 217,660 indirect yes -1.9553 -4.1101 0.6385 3 -4.2698 5

CHACKO JACOB - Director - Officer PRESIDENT AND CEO

2021-09-14 16:01:22 -0400 2021-09-10 S 2,942 $25.08 d 13,609 direct yes -1.9553 -4.1101 0.6385 3 -4.2698 5

HEYMAN RICHARD A. - Director see footnote

2021-09-14 16:03:31 -0400 2021-09-10 S 479 $25.10 d 218,261 indirect yes -1.9553 -4.1101 0.6385 3 -4.2698 5

CHACKO JACOB - Director - Officer PRESIDENT AND CEO

2021-09-09 16:33:10 -0400 2021-09-08 S 200 $25.04 d 16,551 direct yes -2.1302 1.3666 1.3666 6 -2.1302 2

CHACKO JACOB - Director - Officer PRESIDENT AND CEO

2021-09-09 16:33:10 -0400 2021-09-07 S 5,981 $25.11 d 16,751 direct yes -2.1302 1.3666 1.3666 6 -2.1302 2

HEYMAN RICHARD A. - Director see footnote

2021-09-09 16:36:41 -0400 2021-09-07 S 1,086 $25.11 d 218,740 indirect yes -2.1302 1.3666 1.3666 6 -2.1302 2

HOERTER STEVEN L. - Director

2021-08-16 17:56:04 -0400 2021-08-13 A 33,250 a 33,250 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 22:15:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 21:45:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 21:15:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 20:45:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 20:15:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 19:45:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 19:15:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 18:45:03 UTC -0.3696 0.4396 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 18:15:03 UTC -0.3696 0.4396 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 17:45:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 17:15:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 16:45:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 16:15:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 15:45:03 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 15:15:04 UTC -0.3192 0.3892 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 14:45:02 UTC -0.3598 0.4298 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 14:15:02 UTC -0.3598 0.4298 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 13:45:02 UTC -0.3598 0.4298 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 13:15:03 UTC -0.3598 0.4298 900000
ORIC PHARMACEUTICALS INC ORIC 2021-09-24 12:45:03 UTC -0.3598 0.4298 900000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
INVESTMENT MANAGERS SERIES TRUST- 361 Domestic Long/Short Equity Fund ORIC -2180.0 shares, $-52603.4 2021-04-30 N-PORT
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio ORIC -8200.0 shares, $-145058.0 2021-06-30 N-PORT
Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund ORIC -1100.0 shares, $-19459.0 2021-06-30 N-PORT
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund ORIC -2200.0 shares, $-38918.0 2021-06-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ORIC -200.0 shares, $-3538.0 2021-06-30 N-PORT

Elevate your investments